In addition, some studies have found that the proportion of iNKT cells and the expression of CD1d in B cells in individuals with SLE who positively responded to rituximab treatment were significantly increased compared with patients who did not respond to the drug. The gene discussed is CD1D; the disease is systemic lupus erythematosus.